Nalbuphine ER: Relief is Possible

We are developing nalbuphine ER, unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.

Passionate
about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Passionate
about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Are you suffering from or caring for someone with symptoms associated with chronic neurologically mediated conditions?

A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions

We are developing nalbuphine ER as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, nalbuphine ER has the potential to significantly improve the quality of life of patients.

Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients

news

05/29/2020

NEW HAVEN, Conn. , May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due to the public

05/07/2020

Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund Operations into the Fourth Quarter of 2021 NEW HAVEN, Conn. , May 07, 2020 (GLOBE NEWSWIRE) -- Trevi

04/08/2020

NEW HAVEN, Conn. , April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will

contact

Trevi Therapeutics

195 Church Street, 14th Floor
New Haven, CT 06510
map

(203) 304-2499
email us